Abstract: 1-Hetero substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

Abstract: Stereoisomeric substituted and/or unsubstituted octahydronaphthoquinolizines (OHNQs), and derivatives and analogs thereof are provided, including pharmaceutical and diagnostic compositions, as well as methods of making and using these compounds according to the following formula I: ##STR1##

Abstract: A novel chemiluminescent labeling compositions comprising an ester or thiolester covalently and jointly bonded to (1) a carbon of a heterocyclic ring or ring system that is susceptible to attack by peroxide or molecular oxygen and (2) an aryl ring or ring system wherein the heterocyclic ring or ring system is distinquished by a heteroatom thereof in an oxidation state which causes the attacked carbon atom to form an intermediate that decays and produces chemiluminescence; the aryl ring or ring system contains at least three substituents on a six-member aromatic hydrocarbon that together sterically and electronically hinder hydrolysis of the linkage, which substituents involve ortho substituent groups on the aryl in conjunction with quaternary ammonium meta or para substituents thereon.

Abstract: Dye corresponding to the following formula - ##STR1## wherein Z represents CN, COOR.sup.1 or CONR.sup.2 R.sup.3 ;R.sup.1, R.sup.2 and R.sup.3 each independently represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or R.sup.2 and R.sup.3 together represent the necessary atoms to close a heterocyclic nucleus or substituted heterocyclic nucleus;Y represents OR.sup.4 or NR.sup.5 R.sup.6 or CN;R.sup.4 represents hydrogen, substituted or unsubstituted or unsubstituted aryl, SO.sub.2 R.sup.7, COR.sup.7, CSR.sup.7, POR.sup.7 R.sup.8 ;R.sup.5 and R.sup.6 each independently has one of the significances given to R.sup.4 or represents substituted or unsubstituted amino, or R.sup.5 and R.sup.6 together represent the necessary atoms to close a heterocyclic nucleus or substituted heterocyclic nucleus, including a heterocyclic nucleus with an aliphatic or aromatic ring fused-on;R.sup.7 and R.sup.

Abstract: An indole derivative represented by the general formula (I) ##STR1## wherein R is hydrogen, lower alkyl having 1 to 6 carbons, carboxymethyl, or substituted or unsubstituted aralkyl; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may be the same with or different from each other and are hydrogen, halogen, lower alkyl having 1 to 6 carbons, lower alkoxy having 1 to 6 carbons, acyl, substituted or unsubstituted amino, nitro, hydroxy, acyloxy, substituted or unsubstituted aralkyl, substituted or unsubstituted aryloxy, or substituted or unsubstituted aralkyloxy, or a combination of R.sup.2 and R.sup.3 may be methylenedioxy;R.sup.5 is hydrogen, lower alkyl having 1 to 6 carbons, or substituted or unsubstituted aralkyl; R and R.sup.4, or R.sup.1 and R.sup.5 may form together a six-membered ring constituted of methylene chains which may contain a heteroatom;R.sup.6 and R.sup.

Abstract: Annelated indoleketones with an imidazolylalkyl substituent having the formula (2): ##STR1## wherein R.sub.1 is alkyl or alkoxy having 1-4 C-atoms, hydroxy, halogen, trifluoromethyl, a group R.sub.5 R.sub.6 N or R.sub.5 R.sub.6 -N-CO, wherein R.sub.5 and R.sub.6 are hydrogen or alkyl having 1-4 C-atoms or wherein R.sub.5 R.sub.6 N is a saturated 5-6 ring, and n has the value 0, 1 or 2;A is a group of formula 3, 4 or 5 ##STR2## wherein one of the groups R.sub.2, R.sub.3 and R.sub.4 is hydrogen, alkyl having 1-4 C-atoms, cycloalkyl having 3-6 C-atoms or alkenyl having 2-4 C-atoms and the two other groups, independently of each other, are hydrogen or alkyl having 1-4 C-atoms,p has the value 0-3, and q has the value 2-5. These compounds (and pharmaceutically acceptable acid addition salts thereof) have good antagonistic activity of "neuronal" 5-hydroxytryptamine(5-HT)receptors, and the lower toxicity.

Abstract: 1,2,3,4,4a,4b,5,6,7,8,8a,12b-Dodecahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy or alkoxyalkyl)triphenylenes, 2,3,3a,3b,4,5,6,7,7a,11b-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-1H-cyclopenta[1]-phenanthrenes, 2,3,4,4a,4b,5,6,7,8,8a-decahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl)-1H-pyrido[1,2-f]phenanthridines, and 1,2,3,3a,3b,4,5,6,7,7a-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-pyrrolo[1,2-f]phenanthridines and derivatives are valuable as central nervous system active agents or as intermediates to compounds having such activity.

Abstract: The invention relates to novel racemic or optically active berban derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent independently from the other a hydroxyl, straight or branched chain alkoxy group 1 to 6 carbon atoms or R.sup.1 and R.sup.2 together represent a C.sub.1-3 alkylenedioxy group;R.sup.3 and R.sup.4 represent independently from the other hydrogen, straight or branched chain alkyl group, having 1 to 6 carbon atoms and optionally substituted by hydroxyl group, or a C.sub.2-6 alkoxycarbonyl or cyano group; andR.sup.5 represents hydrogen, straight or branched chain alkyl group having 1 to 6 carbon atoms, C.sub.1-7 aliphatic or aromatic acyl group or C.sub.1-7 alkylsulphonyl or arylsulphonyl group, anda salt thereof, to pharmaceutical compositions containing them, to the use as well as to process for preparing the novel compounds. The compounds of the formula (I) are selective .alpha..sub.

Abstract: An enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one provides a key intermediate for the preparation of the .alpha..sub.2 -adrenergic antagonist (2R,12bS)-N-(1,3,4,6,7,12-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl) -N-methyl-2-hydroxyethanesulfonamide hydrochloride, useful as an anti-depressant.

Abstract: Levorotatory enantiomers of the derivatives of 5,6,13,13a-tetrahydro-8H-dibenzo-[a,g]-quinolizine of formula III ##STR1## wherein R'.sub.3 is hydrogen, an aryl or alkyl group or a --OR or --SR moiety wherein R is hydrogen, an aryl or alkyl group or a group of formula: ##STR2## wherein R" is an aryl or alkyl group, R'.sub.10 and R'.sub.11 which are identical or different, represent hydrogen, an aryloxy, alkoxy or hydroxy group or R'.sub.10 and R'.sub.11 taken together form a --O--(CH.sub.2).sub.n --O-- group in which n is 1 to 3.Application to treatment of cardiovascular disorders.

Abstract: 1,2,3,4,4a,4b,5,6,7,8,8a,12b-Dodecahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy or alkoxyalkyl)triphenylenes, 2,3,3a,3b,4,5,6,7,7a,11b-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-1H-cyclopenta[1]-phenanthrenes, 2,3,4,4a,4b,5,6,7,8,8a-decahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl)-1H-pyrido[1,2-f]phenanthridines, and 1,2,3,3a,3b,4,5,6,7,7a-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)pyrrolo[1,2-f]phenanthridines and derivatives are valuable as central nervous system active agents or as intermediates to compounds having such activity.

Abstract: Novel compounds are disclosed, which are derivatives of 1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]-isoquinolines, represented by general formula (I): ##STR1## as well as pharmaceutical compositions and methods for the treatment of depression in warm-blooded animals, e.g., man. Novel intermediates are also part of the invention.

Abstract: 1,2,3,4,4a,4b,5,6,7,8,8a,12b-Dodecahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy or alkoxyalkyl)triphenylenes, 2,3,3a,3b,4,5,6,7,7a,11b-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-1H-cyclopenta[1]phenanthrenes, 2,3,4,4a,4b,5,6,7,8,8a-decahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl)-1H-pyrido[1,2-f]phenanthridines, and 1,2,3,3a,3b,4,5,6,7,7a-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)pyrrolo[1,2-f]phenanthridines and derivatives are valuable as central nervous system active agents or as intermediates to compounds having such activity.

Abstract: 1,2-dihydron-7-oxo-3H,5H-naphtho[1,2,3-ij]quinolizine-6-carboxylic acids are disclosed as active antimicrobial agents as are pharmaceutically acceptable esters, amides, acyl halides and salt derivatives thereof. Intermediates and synthetic processes are also disclosed.

Abstract: Disclosed are a novel dimeric sparteine derivative, the 17S,17'S-bissparteine, and its physiologically compatible acid addition salts. Said compounds are produced by dimerization of 17-hydroxy sparteine or 17-dehydrosparteine salts by means of activated magnesium or an alkali metal. Pharmaceutical compositions containing said novel dimeric sparteine derivatives and their preparation are also described.

Abstract: The invention is a method of increasing femoral blood flow and vertebral blood flow a compound of the formula: ##STR1## wherein R is alkoxy carbonyl the alkoxy having up to 5 carbon atoms, trimethoxy substituted phenyl carbonyl or a therapeutically acceptable acid addition salt of one of the foregoing.

Abstract: Novel lactate salts of 1 and d,l-glaucine are prepared by reacting 1 or d,l-glaucine base with lactic acid. The glaucine salts have potent analgesic and antitussive properties, excellent flavor characteristics and stability properties. Pharmaceutical compositions, and methods of using the same are also described.

Abstract: Compounds of the formula: ##STR1## wherein the symbols X each represent hydrogen or methoxy, R represents hydrogen or carboxymethyl, the symbols R.sub.1 each represent hydrogen or together represent a valency bond and the symbols R.sub.2 each represent hydrogen or together represent a valency bond, the pair of symbols R.sub.2 having the same significance as the pair of symbols R.sub.1, and when the symbols R.sub.1 and R.sub.2 represent hydrogen the symbol X also represents hydrogen, are new compounds possessing antiviral activity.